Recent Updates — SNY
Sanofi broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The project occupies a 36,000-square-meter footprint and leverages advanced digital technologies and artificial intelligence across manufacturing and quality processes. Full production of the active pharmaceutical ingredient is planned for 2032 once the facility receives full licensing. This investment strengthens Sanofi's long-term ability to provide reliable insulin supply to millions of people with diabetes globally, building on more than a century of expertise at the site. Sanofi is an R&D driven biopharmaceutical company focused on inventing medicines and vaccines.
Sanofi announced an expansion of its global alliance with Regeneron to include multiple next-generation, long-acting immunology antibodies. The agreement adds REGN20423, a clinical-stage IL-13 monoclonal antibody, along with a long-acting IL-4xIL-13 bispecific and two pre-clinical antibodies. Sanofi will pay Regeneron an upfront fee of $1 billion, with potential milestone payments up to an additional $7 billion. The companies will equally share development costs, commercialization expenses, and future global profits for these new programs. This strategic move aims to accelerate the creation of therapies for immune-mediated diseases beyond their existing Dupixent collaboration.
Sanofi announced a strategic partnership with Cheplapharm to divest a selection of 20 mature medicines and three manufacturing sites (in Hungary, Singapore, and France) in exchange for a 26.4% equity stake in Cheplapharm. The transaction includes the flagship product Lovenox/Clexane and is expected to close by the third quarter of 2027, subject to regulatory approvals and customary conditions. Sanofi stated the deal would not impact its 2026 financial guidance. This strategic move allows Sanofi to simplify its mature portfolio while Cheplapharm expands its capabilities in well-established medicines.
Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis. The company decided not to submit the drug for global regulatory reviews because the current efficacy and safety evidence does not suggest it would provide a meaningful improvement over existing standards of care. Sanofi is not amending its full-year 2026 guidance due to this decision. Additionally, the company is evolving its Executive Committee effective September 1, 2026, to support its next strategic chapter. Sanofi is a biopharma company that develops medicines and vaccines.
The US Food and Drug Administration (FDA) approved subcutaneous Sarclisa Escena for the treatment of patients with multiple myeloma (MM) across all existing intravenous indications. This marks the first anticancer treatment approved for administration via an on-body injector (OBI) using Enable Injections' CirCLIQ device. The approval follows the phase 3 IRAKLIA study, which demonstrated non-inferiority in efficacy, pharmacokinetics, and safety compared to intravenous administration. The subcutaneous formulation offers a more convenient administration experience for patients and reduces the physical burden on healthcare providers. Sanofi is a biopharma company that develops medicines and vaccines.
Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease. Sanofi is a global healthcare company specializing in pharmaceutical research and development.